Recursion (RXRX): Bathi saben saham sajrone rolas wulan pungkasan

Recursion Pharmaceuticals (RXRX) minimizes biotech risks by utilizing supercomputers to accelerate drug discovery. The 12-month net income per share trend confirms this approach, where -0.89 represents the current value of the metric. The Inertia platform maps biological processes, attracting capital from pharma behemoths. Meanwhile, massive computing expenditures create powerful operating leverage for future large-scale technology licensing.

RXRX Bathi saben saham sajrone 12 wulan pungkasan Recursion Pharmaceuticals, Inc. (04.07.2022 - 10.11.2026)

Rincian metrik komprehensif lan analitis Recursion Pharma (RXRX)

- rega saham lan target rega konsensus:

Rega saham Recursion Pharmaceuticals, Inc.|RXRX - Target median analis

- data kapitalisasi bursa:

Nilai pasar Recursion Pharmaceuticals, Inc.|RXRX - Total Nilai Perusahaan

- data nilai buku modal saham:

Aset Bersih saben Siji Saham Recursion|RXRX - Kapitalisasi Akuntansi|Rasio Kapitalisasi marang Aset Bersih recursion.com|RXRX - Nilai Agregat Aset

- rincian utang lan likuiditas:

Utang marang Ekuitas Recursion Pharmaceuticals|RXRX - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang modal Recursion Corp|RXRX - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Recursion Pharmaceuticals, Inc.|RXRX - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Recursion|Likuiditas cepet recursion.com

- data bathi lan kelipatan valuasi:

RXRX - Penghasilan resik|Proyeksi bathi mangsa ngarep Recursion Pharmaceuticals|RXRX - Pangali P/E|Pangali Forward P/E Recursion|RXRX - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Recursion Pharmaceuticals, Inc.|RXRX - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Recursion|RXRX - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan recursion.com|RXRX - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Recursion Pharmaceuticals

Analisis umum perusahaan:recursion.com (RXRX)

The stability of Recursion Pharmaceuticals (RXRX) is driven by growing demand from major pharma behemoths for AI technologies to accelerate drug development. Analyzing the current trailing 12-month EPS allows for the adjustment of earnings to remove the impact of share issuance, helping investors distinguish the real fundamental trend from price noise and avoid purchasing an overvalued asset by benchmarking against industry metrics.

Pesaing Recursion Pharmaceuticals (RXRX)